Submitted by jwr@option4.com on Sat, 07/17/2010 - 21:09
Activity of Bevacizumab in Combination with First- and Second-Line Chemotherapy for Metastatic Breast Cancer (mBC)
| CME test | Downloadable PDF | PowerPoint slides | CME Information and Faculty Disclosures |
| Read Dr Love's original email (from July 20, 2010) | Subscribe to Dr Love's email alerts | ||
Slides from presentations at ASCO 2010 and transcribed comments from recent interviews with Adam M Brufsky, MD, PhD (6/18/10), Kathy D Miller, MD (6/11/10) and Eric P Winer, MD (7/6/10)
O'Shaughnessy J et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). Proc ASCO 2010;Abstract 1005.
Brufsky A et al. Progression-free survival in patient subgroups in RIBBON-2, a phase III trial of chemotherapy plus or minus bevacizumab for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer. Proc ASCO 2010;Abstract 1021.